Retrospective Cohort Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Apr 7, 2018; 24(13): 1410-1418
Published online Apr 7, 2018. doi: 10.3748/wjg.v24.i13.1410
Table 1 Patients’ demographics and laboratory with n = 52 demonstrating autoimmune hepatitis-induced acute liver failure (9.2%)
Study population (n = 52) with AIH-induced ALF
Mean age (yr)43.6 ± 14.9 (19-76)
Male8 (15.4%)
Female44 (84.6%)
Hepatic encephalopathyGrade I: 46/52 (88.4%)
Grade II: 2/52 (3.8%)
Grade III: 2/52 (3.8%)
Grade IV: 2/52 (3.8%)
Immunosuppressive therapySteroid induction: 52/52 (100%)
Steroid maintenance: 30/52 (57.7%)
Steroid withdrawal: 20/52 (42.3%)
Azathioprine: 27/52 (51.9%)
Cyclosporine A: 7/52 (13.5%)
ALT (U/L)1391.0 (843.5-2154.5)
Total bilirubin (mg/dL)14.3 (11.7-18.7)
Creatinine (mg/dL)0.76 (0.55-0.95)
INR1.78 (1.64-2.00)
LabMELD-score24 (22-26)
Immunoglobulin G (g/L)17.2(13.1-22.8)
γ-globulin-fraction (%)24.5 (19.5-29.3)
Table 2 Patients’ data stratified by recovery and non-recovery (n = 52)
Recovery (n = 43)Non-recovery (n = 9)P value
Age (yr)40.0 (28.0-52.0)49.0 (44.0-62.5)0.031
Male/female7/361/8NS
ALT (U/L)1512 (904-2276)711 (324-1391)0.0157
Total bilirubin (mg/dL)14.0 (11.3-18.7)16.1 (11.8-23.6)NS
Creatinine (mg/dL)0.72 (0.51-0.92)0.98 (0.77-1.61)0.0069
INR1.76 (1.63-1.98)1.96 (1.75-2.79)0.0644
LabMELD-score23 (22-25)27 (25-30)0.0007